Manchester, New Hampshire-based Sequel currently offers twiist for type 1 diabetes, launching earlier this year. It shared ...

MANCHESTER, N.H., March 18, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing state-of-the-art insulin delivery technologies, today announced that Abbott’s FreeStyle Libre 3 Plus ...

Sequel Med Tech, LLC, today announced results from a multi-center pivotal trial evaluating the safety and efficacy of the investigational twiist™ Automated Insulin Delivery (AID) System in adults with ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Senseonics and newcomer pump developer Sequel Med Tech have a plan to connect their diabetes technologies, with the goal of delivering what they describe as the first automated insulin delivery system ...

Full launch of twiist™ AID system powered by Tidepool brings first-ever combination of personalized insulin automation, innovative delivery technology, and CGM interoperability to type 1 diabetes ...

A new partnership had led to the development of the first-ever automated insulin delivery (AID) system that incorporates a 1-year glucose sensor. The twiist AID is approved for people aged 6 years or ...

GERMANTOWN, Md., Jan. 08, 2026 (GLOBE NEWSWIRE) -- Senseonics Holdings, Inc. (NASDAQ: SENS), a medical technology company focused on the development, manufacturing and commercialization of long-term, ...

twiist™ AID system powered by Tidepool expected to launch Q2 2025 in the U.S. with Abbott's FreeStyle Libre® 3 Plus sensor MANCHESTER, N.H., March 18, 2025 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a ...